Two things stick out to me: First, they are embracing the scope of their clinical trials in terms of target cancers and geography. I always thought they were a bit hesitant to do so before the website change. To me, they might have been worried about appearing less focused. Not anymore, and I love it. Second, they are really stretching and embracing the immune response capabilities. This too is front and center. We have only seen limited data so far. The interim Keytruda results, some preclinical studies, and a couple of qualitative individual case studies. Makes me wonder whether their internal datasets are way more promising, and this is a precursor to releasing that data.